Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

NCT03742895 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

329

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Neoplasms

Interventions

DRUG: Olaparib

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]